| Name | Title | Contact Details |
|---|
WebMD is a leading provider of health information services to consumers, physicians, healthcare professionals, employers and health plans.
Aptihealth is improving higher acuity behavioral healthcare for underserved populations—one member at a time. The company`s virtual-first model and proprietary screening, assessment, and treatment programs give members fast, convenient access to precise, personalized care. Headquartered in Boston and employing over 150, aptihealth has raised over $65 million in funding from leading international equity firms. The company`s care program and data insights are driving breakthroughs in mental health understanding, treatment, outcomes, and cost reduction.
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.
County Of Ripley is a Doniphan, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.